Aldose Reductase

Carboxy finasteride is a significant metabolite of the 5α-reductase inhibitor finasteride, targeting aldose reductase. As a biotransformation product of finasteride, it is primarily formed through oxidation by cytochrome P450 (CYP3A4) and represents the predominant metabolite found in urine, while hydroxy finasteride is more prevalent in plasma. This compound plays a crucial role in research related to metabolic pathways and the pharmacokinetics of finasteride, contributing to studies on diabetic complications and related enzymatic activities.

M79175 is an aldose reductase inhibitor that plays a crucial role in the management of diabetic complications. By inhibiting the enzyme, M79175 assists in the reduction of sorbitol accumulation, which is implicated in the pathogenesis of diabetic retinopathy. This reagent is relevant for researchers investigating early stages of diabetic retinopathy and potential therapeutic strategies for diabetes-related ocular disorders.

AL-4114 is a potent aldose reductase inhibitor that plays a critical role in the management of diabetic complications. This compound has demonstrated significant biological activity in the prevention of diabetic cataractogenesis, making it valuable for research focused on diabetes-related ocular disorders. Its application extends to the investigation of metabolic pathways and the development of therapeutic strategies for diabetes management.

ALO1567 is an orally available aldose reductase inhibitor that demonstrates an IC50 of 27 nM against rat lens aldose reductase. This compound is utilized in research focused on diabetes, particularly in studying the pathways related to hyperglycemia and osmotic stress in diabetic complications. Its specific targeting of aldose reductase makes it a valuable tool for investigating therapeutic strategies in metabolic disorders.

Salfredin A7 is an aldose reductase inhibitor that targets the enzyme responsible for converting glucose into sorbitol. This activity is significant in the context of diabetic complications, where the accumulation of sorbitol leads to cellular damage. Salfredin A7 exhibits anti-inflammatory properties and has potential applications in research focusing on diabetes-related pathologies and oxidative stress. Its inhibitory action on aldose reductase makes it a valuable reagent for studies investigating metabolic diseases and their associated complications.

Zopolrestat is a potent inhibitor of aldose reductase (AR) with an IC50 of 3.1 nM. This compound is primarily utilized in research focused on diabetic complications, providing insights into the metabolic pathways involved in diabetes-related disorders. Its application extends to studying the therapeutic potential in mitigating diabetic neuropathy and retinopathy, making it a valuable tool in diabetes research.

Ganoderic acid C2 is a bioactive triterpenoid that functions as an aldose reductase inhibitor, displaying an IC50 of 43.8 µM. This compound exhibits potential anti-tumor activity along with antihistamine and anti-aging properties. Its cytotoxic effects make Ganoderic acid C2 a valuable reagent for research in fields such as cancer biology and metabolic disorders.

6-Hydroxyluteolin is a flavonoid identified as an aldose reductase inhibitor. It demonstrates potential antidiabetic activity by reducing the conversion of glucose to sorbitol, thereby mitigating osmotic and oxidative stress in diabetic tissues. This compound is useful in research applications focused on diabetes-related complications and metabolic disorders.

Zenarestat is a potent and orally active inhibitor of aldose reductase, an enzyme involved in the polyol pathway. This compound demonstrates significant biological activity by improving symptoms of diabetic peripheral neuropathy in preclinical models, specifically in Zucker diabetic fatty rats. Zenarestat may serve as a valuable tool for research into diabetic complications and the modulation of glucose-related metabolic disorders.

Exisulind is an aldose reductase inhibitor with an IC50 of 367 nM in vitro. As an inactive metabolite of sulindac, it may play a role in mitigating complications associated with type 2 diabetes through its pharmacological effects. This compound is valuable for research focused on metabolic disorders and the management of diabetes-related complications.

Lidorestat is a potent and selective aldose reductase inhibitor, exhibiting an IC50 of 5 nM. This compound is primarily used in research focused on chronic complications associated with diabetes. It has demonstrated efficacy in enhancing nerve conduction and reducing the formation of cataracts, making it valuable for studies relating to diabetic neuropathy and cataractogenesis.

Ganoderic acid C6 functions as an aldose reductase inhibitor, effectively modulating glucose metabolism. This compound is important for research aimed at understanding diabetic complications and oxidative stress management. Its potential to influence pathways associated with diabetic neuropathy and retinopathy makes it a valuable reagent for investigating therapeutic strategies in metabolic disorders.